Navigation Links
Independent publication supports the profile of CeNeS phase II,compound, CNS 5161

CAMBRIDGE, England, 4th May 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, notes the publication of an independent study in the respected scientific journal 'Synapse'* on its Phase II NMDA antagonist, CNS 5161. CeNeS is developing CNS 5161 as a potential treatment for neuropathic pain. The independent study builds on the work that CeNeS has already undertaken with CNS 5161.

In the study reported in 'Synapse', Dr Anat Biegon and her group at the Brookhaven National Laboratory, New York, USA, have studied a radioactively labelled version of CNS 5161. They have shown that CNS 5161 is a selective and high affinity NMDA receptor antagonist with preferential binding to the activated form of the receptor. The group also demonstrated that CNS 5161 penetrates the brain well and can be used to label selectively brain NMDA receptors in vivo. Dr Biegon proposes that a radioactive form of CNS 5161 may be used as an agent to monitor NMDA receptors in the human brain using Positron Emission Tomography ("PET") and notes that "the significance of a selective, validated radiopharmaceutical agent suitable for detecting widespread as well as highly localized changes in the NMDA receptor in the living brain cannot be exaggerated".

Data from Phase I and Phase IIa studies previously carried out by CeNeS have shown that CNS 5161 has analgesic properties in patients with neuropathic pain, but does not induce the severe psychotomimetic side-effects associated with other NMDA antagonists.

Neil Clark, Chief Executive of CeNeS, said:

"The data published in this paper supports and extends our original findings with CNS 5161. It has proved very difficult to develop a PET agent with the properties that make it possible to monitor NMDA receptor activation in the human brain. The profile of CNS 5161 as a selective, high affinity and brain-penetrating agent now make this a
'"/>




Page: 1 2 3

Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
4. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
5. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
6. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
7. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
8. CeNeS Pharmaceuticals plc: Update on Successful Phase III results announced on Lead Product M6G
9. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
10. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
11. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial

Post Your Comments:
(Date:11/6/2009)...ESEARCH TRIANGLE PARK, N.C., Nov. 6 /PRNewswire/ -...ncing orally-available antiviral therapeutics to a...s on the development of the company,s lead antivir...ion (WHO) and the Global Health Security Initiativ...ent being developed for the treatment of smallpox,...
(Date:11/6/2009)...TLANTA, Nov. 6 GeoVax L... "the Company"), an Atlanta-based, biopharmaceutic...caused by HIV-1 (Human Immunodeficiency Virus) and...d quarter 2009 financial results and provided an o...esident and Chief Executive Officer commented, "We...
(Date:11/6/2009)...ETROIT, Nov. 6 Caraco Ph... has launched ketorolac tromethamine ophthalmic so...S Food and Drug Administration (FDA) for Sun Pharm...neric Acular® opthalmic solution on the first... ketorolac is therapeutically equivalent to Acular...
Breaking Medicine Technology:Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 2Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2New Drug Promising Against Rheumatoid Arthritis 50263 1New Drug Promising Against Rheumatoid Arthritis 50263 2Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non Small Cell Lung Cancer Drug Market to Nearly Triple to Almost 2 50258 1Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non Small Cell Lung Cancer Drug Market to Nearly Triple to Almost 2 50258 2Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non Small Cell Lung Cancer Drug Market to Nearly Triple to Almost 2 50258 3DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 1DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 2DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 3DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 4DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 5DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 6
...ia Ltd, a specialty,biopharmaceutical company focu...ted a phase II clinical study of its ToleroMune(R)...rial builds on positive phase II results,that demo...Mune allergy,therapy, and extends clinical investi... The lastest study, which is underway in Canad...
...grape skin powder, from Muscadine Naturals, Inc ...ed significant protection against radiation damage...inding was reported in April of 2009 at the 100th ...cer Research, in Denver, Colorado. , , (Logo: ...15 ) , , The results were reported by Dr. Ron...
Other Medicine Technology:Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients 2Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects 2
(Date:11/8/2009)...v. 7 Today, the House o..., Dahlkemper, Smith, Ellsworth and Lipinski amendm..." (H.R. 3962). The amendment maintains the current... and for benefits packages that include abortion. ...ive affordability credits and those who do not, ca...
(Date:11/8/2009)...ft Passage of H.R. 3961 to Secure the Stability of...swire/ -- Statement Attributable to: J. James Roha... ,, (Logo: http://www.newscom.com/cgi-bin/prn...ssage of the House health reform bill, which will ...ysicians and calls for swift passage of H.R. 3961 ...
(Date:11/8/2009)...if., Nov. 8 March of Di... luncheon to recognize prominent individuals who a... are role models for March of Dimes commitment to ...h of Dimes November Prematurity Awareness Month ca...to join the fight for preemies! ,, (Photo: ht...
(Date:11/7/2009)...Coleman (CT), David A. Cook (GA), Louis J. Goodman...Honored ,, CHICAGO, Nov. 7 /PRNewswire-USNewsw...ay presented five medical society executive leader...ions to the goals and ideals of the medical profes...annual policy making meeting in Houston. ,, (L...
(Date:11/7/2009)...v. 7 The U.S. bishops N...tives to vote for the Stupak-Ellsworth Amendment t...rth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendme...ion funding and conscience protections in the Affo...hey said. ,, The letter was signed by Cardinal ...
Breaking Medicine News(10 mins):Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3Health News:AMA Honors Medical Society Executives 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2
...!(R) Clip-On(TM) Mosquito Repellent Helps Protect ...ACINE, Wis., May 6 More women are turning to the ...According to the recent OFF! (R) Clip-On(TM) Mosqu...of women admit they,ve actually avoided outdoor ac...
...an,t predict whether it will be more virulent or n...- Many experts are predicting that the current out... flu, will subside during the summer months and re...Dr. Len Horovitz, a pulmonary specialist with Leno...
...eonatal studies indicate cerebral/somatic oximetry...ase states and guide patient management , , TROY,...MTS ) announced today that its INVOS(R) System was...es focused on early applications of the technology...
...ed Product Review Body Recognizes Dance It! for It...KA, Minn., May 6 Dancercise Kids(R), a provider o...ng children, today announced that its founder, Tes...CD "really impressed ... with its ability to enter...
...FORD, Pa., May 6 Endo Pharmaceuticals (Nasdaq: ... Bank of America and Merrill Lynch 2009 Health Car...m Eastern Time. Dave Holveck, President and Chief...d from Endo,s website at www.endo.com under th...
...Korea, May 6 Korea,s leading university hospital h...diotherapy that potentially enables doctors to imp...patients. A 17-year-old female with cancer in her ...cians at Ajou University Hospital in Suwon, which ...
Other Medicine News:Health News:Women Seek Outdoor Solace This Summer 2Health News:Women Seek Outdoor Solace This Summer 3Health News:Swine Flu Likely to Return to U.S. Next Winter 2Health News:Swine Flu Likely to Return to U.S. Next Winter 3Health News:Swine Flu Likely to Return to U.S. Next Winter 4Health News:25 Clinical Abstracts at National Conference Spotlight Clinical Utility of Somanetics INVOS System in Neonates 2Health News:25 Clinical Abstracts at National Conference Spotlight Clinical Utility of Somanetics INVOS System in Neonates 3Health News:25 Clinical Abstracts at National Conference Spotlight Clinical Utility of Somanetics INVOS System in Neonates 4Health News:Tessa, of Dancercise Kids, Wins the National Parenting Center's Seal of Approval for New Children's Music CD 2Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 3Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 4Health News:Ajou University Hospital Becomes First in Korea to Treat Using RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 2Health News:Ajou University Hospital Becomes First in Korea to Treat Using RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 3
...nd effective resection of meniscal tears while rec.... The flat, crescent-shaped tip has an extremely l...s. Made in the U.S. at Arthrex California, Inc., 2...and instrument design guarantees unsurpassed stren...
...nd effective resection of meniscal tears while rec.... The flat, crescent-shaped tip has an extremely l...s. Made in the U.S. at Arthrex California, Inc., 2...and instrument design guarantees unsurpassed stren...
...p ratchet disengagement allowing smooth, ratchet-f...ffers state-of-the-art quality in an instrument of... and durability. Low profile cutting tips allow ac...instruments are available in just about every cutt...
...p ratchet disengagement allowing smooth, ratchet-f...ffers state-of-the-art quality in an instrument of... and durability. Low profile cutting tips allow ac...instruments are available in just about every cutt...
Medicine Products: